These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10984267)

  • 1. Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess.
    MacFarlane J; Korbonits M
    Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101910. PubMed ID: 38981769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
    Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
    Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly.
    Haberbosch L; Strasburger CJ
    Arch Med Res; 2023 Dec; 54(8):102884. PubMed ID: 37659952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The position of combined medical treatment in acromegaly.
    Coopmans EC; van Meyel SWF; van der Lely AJ; Neggers SJCMM
    Arch Endocrinol Metab; 2019; 63(6):646-652. PubMed ID: 31939490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Code Expansion Enables Site-Specific PEGylation of a Human Growth Hormone Receptor Antagonist through Click Chemistry.
    Tamshen K; Wang Y; Jamieson SMF; Perry JK; Maynard HD
    Bioconjug Chem; 2020 Sep; 31(9):2179-2190. PubMed ID: 32786367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegvisomant for acromegaly: does it always works?
    Neggers SJ; Lely AJV
    Arch Endocrinol Metab; 2019 Aug; 63(4):318-319. PubMed ID: 31460621
    [No Abstract]   [Full Text] [Related]  

  • 7. Growth hormone receptor agonists and antagonists: From protein expression and purification to long-acting formulations.
    Wang Y; Kim M; Buckley C; Maynard HD; Langley RJ; Perry JK
    Protein Sci; 2023 Sep; 32(9):e4727. PubMed ID: 37428391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hunger & satiety signals: another key mechanism involved in the NAFLD pathway.
    López-Méndez I; Maldonado-Rojas ADC; Uribe M; Juárez-Hernández E
    Front Endocrinol (Lausanne); 2023; 14():1213372. PubMed ID: 37753211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary hormones are specifically expressed in trigeminal sensory neurons and contribute to pain responses in the trigeminal system.
    Hovhannisyan AH; Son H; Mecklenburg J; Barba-Escobedo PA; Tram M; Gomez R; Shannonhouse J; Zou Y; Weldon K; Ruparel S; Lai Z; Tumanov AV; Kim YS; Akopian AN
    Sci Rep; 2021 Sep; 11(1):17813. PubMed ID: 34497285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
    Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
    Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory investigations in the diagnosis and follow-up of GH-related disorders.
    Schilbach K; Bidlingmaier M
    Arch Endocrinol Metab; 2019; 63(6):618-629. PubMed ID: 31939487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
    Parkinson C; Trainer PJ
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone receptor antagonists therapy for acromegaly.
    Parkinson C; Trainer PJ
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):419-30. PubMed ID: 10909433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
    Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
    Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
    Tritos NA; Biller BM
    Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of GH antagonism in patients with acromegaly.
    Trainer PJ
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.